Sort   by:  
 Page size 
MetabolomicsMapping human microbiome drug metabolism by gut bacteria and their genes

Individuals vary widely in their drug responses, which can be dangerous and expensive due to treatment delays and adverse effects. Growing evidence implicates the gut microbiome in this variability, however the molecular mechanisms remain largely unknown. We measured the ability of 76 diverse hum...

2019-07-10 | MTBLS896 | MetaboLights
MetabolomicsInvestigation of the threonine metabolism of Echinococcus multilocularis: EmTDH as a potential drug target in alveolar echinococcosis
Alveolar echinococcosis is a severe zoonotic disease caused by the fox tapeworm E. multilocularis. New treatment options are urgently needed. Whole-organism-based screening allows the discovery of potential new anti-echinococcal compounds, but suffers from low- to medium-throughput. An alternative a...
2026-09-14 | MTBLS10738 | MetaboLights
MetabolomicsMolecular networking coupled to high-resolution mass spectrometry fragmentation reveals a multitude of urinary antihypertensive drug metabolites
Mass spectrometry is the current technique of choice in studying drug metabolism. High-resolution mass spectrometry (HR-MS) in combination with fragment analysis (MS/MS) has the potential to contribute to rapid advances in this field. However, the data emerging from such fragmentation spectra pose c...
2016-05-23 | MTBLS307 | MetaboLights
MetabolomicsUntargeted metabolomics for triaging of cytochrome b inhibitors during Chagas’ disease drug discovery

Chagas’ disease, caused by infection with the protozoan parasite Trypanosoma cruzi, is a potentially fatal condition for which new treatments are urgently needed. Due to the lack of validated drug targets, phenotypic screening followed by target deconvolution is the dominant approach in Chagas’ d...

2026-01-12 | MTBLS13510 | MetaboLights
MetabolomicsSubcellular antibiotic visualization reveals a dynamic drug reservoir in infected macrophages
Tuberculosis, caused by the intracellular pathogen Mycobacterium tuberculosis, remains the world's deadliest infectious disease. Sterilizing chemotherapy requires at least 6 months of multidrug therapy. Difficulty visualizing the subcellular localization of antibiotics in infected host cells means t...
2020-12-07 | MTBLS959 | MetaboLights
MetabolomicsMetabolomics reveals molecular signatures for psoriasis biomarkers and drug targets discovery
Psoriasis is a chronic skin disease that affects multiple systems and can be influenced by immunological, environmental, and genetic factors. The discovery of plasma biomarkers of psoriasis and the regulation of metabolic pathways helps us understand psoriasis and may assist clinicians in the diagno...
2024-09-26 | MTBLS5185 | MetaboLights
MetabolomicsRepurposing the orphan drug nitisinone to control the transmission of African trypanosomiasis
Tsetse transmit African trypanosomiasis, which is a disease fatal to both humans and animals. A vaccine to protect against this disease does not exist so transmission control relies on eliminating tsetse populations. Although neurotoxic insecticides are the gold standard for insect control, they neg...
2021-10-06 | MTBLS2166 | MetaboLights
MetabolomicsMetabolic Drug Response Phenotyping in Colorectal Cancer Organoids by LC-QTOF-MS
As metabolic rewiring is crucial for cancer cell proliferation, metabolic phenotyping of patient-derived organoids is desirable to identify drug-induced changes and trace metabolic vulnerabilities of tumor subtypes. We established a novel protocol for metabolomic and lipidomic profiling of colorecta...
2021-10-12 | MTBLS2130 | MetaboLights
MetabolomicsAnti-anemia drug FG4592 retards the AKI to CKD transition by improving vascular regeneration and anti-oxidative capability (day 10)

Acute kidney injury (AKI) is a known risk factor for the development of chronic kidney disease (CKD), with no satisfactory strategy to prevent the progression of AKI to CKD. Damage to the renal vascular system and subsequent hypoxia are common contributors to both AKI and CKD. Hypoxia inducible f...

2021-07-22 | MTBLS3056 | MetaboLights
MetabolomicsAnti-anemia drug FG4592 retards the AKI to CKD transition by improving vascular regeneration and anti-oxidative capability (day 21)

Acute kidney injury (AKI) is a known risk factor for the development of chronic kidney disease (CKD), with no satisfactory strategy to prevent the progression of AKI to CKD. Damage to the renal vascular system and subsequent hypoxia are common contributors to both AKI and CKD. Hypoxia inducible f...

2021-07-22 | MTBLS3003 | MetaboLights
Sort   by:  
 Page size